Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
JAMA Netw Open ; 4(11): e2132262, 2021 11 01.
Article in English | MEDLINE | ID: mdl-34762112

ABSTRACT

Importance: In the IMspire150 trial, triplet treatment with atezolizumab and vemurafenib plus cobimetinib significantly improved progression-free survival (PFS) compared with vemurafenib plus cobimetinib alone for treatment of BRAF V600 variation metastatic melanoma. However, considering high cost of this combination, it is unclear if the incremental cost is worth the additional survival benefit. Objective: To evaluate the cost-effectiveness of atezolizumab and vemurafenib plus cobimetinib vs vemurafenib plus cobimetinib alone in patients with newly diagnosed unresectable BRAF V600 variation metastatic melanoma from the US health care perspective. Design, Setting, and Participants: This economic evaluation study used a 3-state partitioned survival model to assess the cost-effectiveness of the combination of atezolizumab with vemurafenib plus cobimetinib vs vemurafenib plus cobimetinib alone. The observed Kaplan-Meier curves for overall survival and PFS were digitized from the IMspire150 trial (January 2017-April 2018) and the long-term survivals (over a lifetime horizon) beyond the end of the trial were extrapolated using 7 different survival models. The cost and health preference data were collected from a literature review. This study was performed from March 2021 through June 2021. Main Outcomes and Measures: The outcomes of interest were expected life-years (LYs) gained and quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratio (ICER), expressed as cost per LYs and per QALYs saved. Results: Adding atezolizumab to vemurafenib and cobimetinib provided an additional 3.267 QALYs compared with the doublet regimen of vemurafenib plus cobimetinib, at an ICER of $271 669 per QALY, which is not considered cost-effective at the willingness-to-pay threshold of $150 000 per QALY. However, the scenario analyses found that atezolizumab combined with vemurafenib plus cobimetinib could be cost-effective at 20-year (ICER, $121 432 per QALY) and 30-year ($98 092 per QALY) time horizons when both strategies were stopped after 2 years of treatments, and over a lifetime horizon ($122 220 per QALY) when only immunotherapy with atezolizumab was stopped after 2 years of treatment. Conclusions and Relevance: These findings suggest that the atezolizumab and vemurafenib plus cobimetinib regimen provides significant survival benefits over vemurafenib plus cobimetinib alone, and a price reduction would be encouraged to maximize the value of its survival gain.


Subject(s)
Antibodies, Monoclonal, Humanized/economics , Antineoplastic Agents/economics , Antineoplastic Combined Chemotherapy Protocols/economics , Azetidines/economics , Melanoma/economics , Melanoma/therapy , Piperidines/economics , Vemurafenib/economics , Antibodies, Monoclonal, Humanized/therapeutic use , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cost-Benefit Analysis , Humans , Immunotherapy/economics , Immunotherapy/methods , Melanoma/mortality , Melanoma/pathology , Neoplasm Metastasis/therapy , Progression-Free Survival , Proto-Oncogene Proteins B-raf , Quality-Adjusted Life Years , Vemurafenib/therapeutic use
2.
Value Health Reg Issues ; 20: 103-109, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31174179

ABSTRACT

OBJECTIVE: To estimate the incremental cost-utility ratio (ICUR) of isolated and combined targeted therapy regimens compared to dacarbazine for first-line treatment of advanced and metastatic melanoma with BRAF V600 mutation. METHODS: A Markov model with three health states (no progression, progression and death), monthly duration cycle and 10-year time horizon was constructed to compare targeted therapy regimens (vemurafenib, dabrafenib, vemurafenib/cobimetinib and dabrafenib/trametinib) with dacarbazine chemotherapy under the Brazilian public health perspective. One-way and probabilistic sensitivity analyses were performed. RESULTS: Mean cost was R$5662.50 ($1490.13) for dacarbazine, R$175 937.18 (46 299.26) for vemurafenib, R$167 461.70 ($44 068.87) for dabrafenib, R$425 901 ($112 079.21) for vemurafenib/cobimetinib and R$411 799.81 ($108 368.37) for dabrafenib/trametinib, whereas QALY was 0.91 for dacarbazine, 1.08 for vemurafenib, 1.12 for dabrafenib, 1.64 for vemurafenib/cobimetinib and 1.56 for dabrafenib/trametinib. The ICUR was estimated from R$572 165.76 ($150 569.94) to R$1 012 524.56 ($266 453.83) per patient, and the most impactful parameters were risk of progression and death, and treatment cost. CONCLUSION: The incorporation of targeted therapies in the Brazilian public health system would produce an additional expenditure of at least 19 times the national GDP per capita to increase in one year the quality-adjusted survival of each patient with advanced/metastatic BRAF-mutant melanoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Dacarbazine/therapeutic use , Health Care Costs/statistics & numerical data , Melanoma/drug therapy , Antineoplastic Agents/economics , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Azetidines/administration & dosage , Azetidines/economics , Azetidines/therapeutic use , Brazil , Cost-Benefit Analysis , Dacarbazine/economics , Drug Costs , Humans , Imidazoles/administration & dosage , Imidazoles/economics , Imidazoles/therapeutic use , Melanoma/economics , Oximes/administration & dosage , Oximes/economics , Oximes/therapeutic use , Piperidines/administration & dosage , Piperidines/economics , Piperidines/therapeutic use , Pyridones/administration & dosage , Pyridones/economics , Pyridones/therapeutic use , Pyrimidinones/administration & dosage , Pyrimidinones/economics , Pyrimidinones/therapeutic use , Vemurafenib/administration & dosage , Vemurafenib/economics , Vemurafenib/therapeutic use
3.
Eur J Health Econ ; 19(8): 1163-1172, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29524005

ABSTRACT

BACKGROUND: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients. OBJECTIVE: To evaluate the cost effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. METHODS: A Markov state-transition model was developed to estimate the lifetime costs and benefits of nivolumab versus ipilimumab and dacarbazine for BRAF mutation-negative patients and versus ipilimumab, dabrafenib, and vemurafenib for BRAF mutation-positive patients. Covariate-adjusted parametric curves for time to progression, pre-progression survival, and post-progression survival were fitted based on patient-level data from two trials and long-term ipilimumab survival data. Indirect treatment comparisons between nivolumab, ipilimumab, and dacarbazine were informed by these covariate-adjusted parametric curves, controlling for differences in patient characteristics. Kaplan-Meier data from the literature were digitised and used to fit progression-free and overall survival curves for dabrafenib and vemurafenib. Patient utilities and resource use data were based on trial data or the literature. Patients are assumed to receive nivolumab until there is no further clinical benefit, assumed to be the first of progressive disease, unacceptable toxicity, or 2 years of treatment. RESULTS: Nivolumab is the most cost-effective treatment option in BRAF mutation-negative and mutation-positive patients, with incremental cost-effectiveness ratios of £24,483 and £17,362 per quality-adjusted life year, respectively. The model results are most sensitive to assumptions regarding treatment duration for nivolumab and the parameters of the fitted parametric survival curves. CONCLUSIONS: Nivolumab is a cost-effective treatment for advanced melanoma patients in England.


Subject(s)
Antineoplastic Agents, Immunological/economics , Antineoplastic Agents, Immunological/therapeutic use , Melanoma/drug therapy , Nivolumab/economics , Nivolumab/therapeutic use , Skin Neoplasms/drug therapy , Age Factors , Aged , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Antineoplastic Combined Chemotherapy Protocols/economics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cost-Benefit Analysis , Dacarbazine/economics , Dacarbazine/therapeutic use , Disease Progression , Disease-Free Survival , Female , Health Expenditures , Health Resources/economics , Health Resources/statistics & numerical data , Humans , Imidazoles/economics , Imidazoles/therapeutic use , Ipilimumab/economics , Ipilimumab/therapeutic use , Kaplan-Meier Estimate , Male , Markov Chains , Middle Aged , Models, Economic , Nivolumab/administration & dosage , Nivolumab/adverse effects , Oximes/economics , Oximes/therapeutic use , Proto-Oncogene Proteins B-raf/genetics , Quality-Adjusted Life Years , Sex Factors , Vemurafenib/economics , Vemurafenib/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...